ImmuCell Corporation Inc (ICCC) - יחס מחיר להכנסות חזויות

The forward P/S multiple illustrates the market valuation dynamics of ImmuCell Corporation (ICCC), with the value of 3.00 serving as the current metric. Business revenues are based on the sale of First Defense biologicals for calf protection. The environmental contribution consists of reducing antibiotic use in livestock farming. Operational stability is ensured by diversified raw material procurement and streamlined logistics within the US.

The forward P/S is calculated as the quotient of the current market capitalization to the expected annual sales volume, measuring the premium the market is willing to pay per unit of future revenue. For ImmuCell Corporation (ICCC), this forward price-to-sales ratio reflects market expectations regarding the scaling of First Defense antibody production and the expansion of manufacturing capacities within the agricultural sector.